恒瑞医药：公司自主研发的1类创新药瑞拉芙普α注射液已于2026年1月在国内获批上市

Core Viewpoint - Heng Rui Medicine emphasizes a differentiated research and development strategy focused on clinical needs, leveraging advanced technology platforms to create a matrix of differentiated innovative products [1] Group 1: Product Development - The company has developed the first-in-class innovative drug, Ruilafup α injection, which was approved for domestic market in January 2026, marking it as the world's first approved anti-PD-L1/TGF-βRII bispecific antibody fusion protein [1] - There are over 100 self-innovated products currently in clinical development, many of which have the potential to be first-in-class or best-in-class [1] Group 2: Future Strategy - The company plans to continue exploring international cutting-edge drug targets that have the potential to be first-in-class or best-in-class, aiming to continuously produce differentiated and competitively innovative products [1]